Connect Biopharma Holdings Limited Revenue Growth Rates (CNTB), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Connect Biopharma Holdings Limited  (NASDAQ: CNTB)
 

CNTB's Revenue Growth by Quarter and Year

Connect Biopharma Holdings Limited's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

CNTB Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -
2nd Quarter June 2.77
1st Quarter March 0.17
FY 2.94





CNTB Revenue second quarter 2026 Y/Y Growth Comment
Connect Biopharma Holdings Limited achieved in the second quarter 2026, above Company average Revenue surge of 5436% year on year, to $ 2.77 millions.

Looking into second quarter 2026 results within Major Pharmaceutical Preparations industry 6 other companies have achieved higher Revenue growth. While Connect Biopharma Holdings Limited' s Revenue doubling of 5436% ranks overall at the positon no. 22 in the second quarter 2026.


CNTB Revenue ( Y/Y Growth %) 2026
 2025 2024 2023
4th Quarter December - - - -
3rd Quarter September - -98.36 % - -
2nd Quarter June 5436 % -99.79 % - -
1st Quarter March - - - -
FY   - -99.86 % - -

Financial Statements
Connect Biopharma Holdings Limited's second quarter 2026 Revenue $ 2.77 millions CNTB's Income Statement
Connect Biopharma Holdings Limited's second quarter 2025 Revenue $ 0.05 millions Quarterly CNTB's Income Statement


CNTB Revenue (Quarter on Quarter Growth %)

 2026
 2025 2024 2023
4th Quarter December - - 2033.61 % -
3rd Quarter September - -60 % -94.94 % -
2nd Quarter June 1528.24 % - - -
1st Quarter March - - - -
FY (Year on Year)   - -99.86 % - -


Back to CNTB Growth rate Comparisons >> Back to CNTB Growth rate Comparisons >>


Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #7
Healthcare Sector #9
Overall #22

Revenue Y/Y Growth Statistics
High Average Low
2035.6 % 535.31 % -100 %
(Dec 31 2024)   (Dec 31 2025)
Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #7
Healthcare Sector #9
Overall #22
Revenue Y/Y Growth Statistics
High Average Low
2035.6 % 535.31 % -100 %
(Dec 31 2024)   (Dec 31 2025)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Connect Biopharma Holdings Limited's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
2035.6 % 535.31 % -100 %
(Dec 31 2024)  


CNTB's II. Quarter Q/Q Revenue Comment
Connect Biopharma Holdings Limited achieved in the II. Quarter 2026 above company average sequential Revenue doubling of 1528.24%, to $ 2.77 millions, from $0.17 millions in the first quarter.
CNTB is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Major Pharmaceutical Preparations industry 6 other companies have achieved higher Revenue quarter on quarter growth. While Connect Biopharma Holdings Limited's Revenue growth quarter on quarter, overall rank is 22.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #7
Healthcare Sector #9
Overall #22
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #7
Healthcare Sector #9
Overall #22
Revenue Q/Q Growth Statistics
High Average Low
2035.6 % 535.31 % -100 %
(Dec 31 2024)  


CNTB's II. Quarter Q/Q Revenue Comment
Connect Biopharma Holdings Limited achieved in the II. Quarter 2026 above company average sequential Revenue doubling of 1528.24%, to $ 2.77 millions, from $0.17 millions in the first quarter.
CNTB is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Major Pharmaceutical Preparations industry 6 other companies have achieved higher Revenue quarter on quarter growth. While Connect Biopharma Holdings Limited's Revenue growth quarter on quarter, overall rank is 22.


Connect Biopharma Holdings Limited's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending
(Mar 31 2026)		 12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 0.00 $ 0.00 $ 0.00 $ 0.00 $ 0.00
Y / Y Revenue Growth (TTM) - - - - -
Year on Year Revenue Growth Overall Ranking # # # # #
Seqeuential Revenue Change (TTM) - - - - -
Seq. Revenue Growth (TTM) Overall Ranking # # # # #


Cumulative Revenue growth Comment
In the Jun 30 2026 period, Connect Biopharma Holdings Limited's cumulative trailing twelve month Revenue remained unchanged compare to the same period a year ago.

Connect Biopharma Holdings Limited achieved highest trailing twelve month year on year Revenue growth. While overall Revenue growth ranking, remained unchanged compare to the previous quarter at no. .

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Revenue TTM Y/Y Growth Statistics
High Average Low
0 %
 0 %
0 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #
Cumulative Revenue growth Comment
In the Jun 30 2026 period, Connect Biopharma Holdings Limited's cumulative trailing twelve month Revenue remained unchanged compare to the same period a year ago.

Connect Biopharma Holdings Limited achieved highest trailing twelve month year on year Revenue growth. While overall Revenue growth ranking, remained unchanged compare to the previous quarter at no. .


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Revenue TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
CNTB's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue doubling for the quarter ending Jun 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2026
Meiragtx Holdings Plc8,608.59%$ 8,608.588 millions
Nakamoto Inc 6,129.94%$ 6,129.943 millions
Connect Biopharma Holdings Limited5,666.67%$ 5,666.667 millions
Hcw Biologics Inc 3,828.21%$ 3,828.214 millions
Protagonist Therapeutics inc 3,749.17%$ 3,749.171 millions
Aligos Therapeutics Inc 2,778.55%$ 2,778.549 millions


About Connect Biopharma Holdings Limited Revenue Growth Rates (CNTB), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Connect Biopharma Holdings Ltd (CIK 1835268).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001835268-26-000028
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Connect Biopharma Holdings Ltd’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.